GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ADMA Biologics
ADMA Biologics is a biopharmaceutical company specializing in plasma-based therapies. Its stock price is dependent on plasma collection volumes, regulatory approvals, and sales of its specialized immunoglobulins for the treatment of immunodeficiency.
Share prices of companies in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company specializing in plasma-based therapies. We classify it as a Pharma-Immune company, and the chart below reflects the overall dynamics of this market segment.
Broad Market Index - GURU.Markets
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based medications, specifically immunoglobulins. As a component of the GURU.Markets index, it operates in the niche biopharmaceuticals sector. The chart below represents the entire market. See how ADMA shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ADMA - Daily change in the company's share price ADMA Biologics
ADMA Biologics, a biopharmaceutical company, has seen its price fluctuate, reflecting the sector's high volatility. Change_co shows its sensitivity to sales of its plasma-based drugs and regulatory news. This metric is key to analyzing the niche biopharma sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
ADMA Biologics, Inc. is a biopharmaceutical company. This chart highlights the sector's high volatility. Comparing it to ADMA, which specializes in plasma-derived therapeutics, helps understand its unique risk profile in this niche.
Daily change in the price of a broad market stock, index - GURU.Markets
ADMA Biologics is a biopharmaceutical company specializing in plasma-based therapies and immunoglobulins. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing ADMA stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ADMA Biologics
ADMA Biologics is a biopharmaceutical company specializing in plasma-based therapies and immunoglobulins. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
ADMA Biologics, Inc. is a biopharmaceutical company specializing in the production and sale of plasma-based products. Its vertical integration (from plasma collection to drug sales) is its key advantage. The chart below shows how its unique niche strategy impacts its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ADMA Biologics, which produces plasma-based medications, operates in the niche and protective healthcare sectors. Demand for its products is stable and unaffected by economic cycles. The company's stock performance reflects its success in ramping up production and securing approvals, rather than general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ADMA Biologics
ADMA Biologics, a biopharmaceutical company, depends on its operational growth for its market capitalization. The monthly fluctuations on the chart reflect the growth of its plasma-based product sales and the success of its plasma collection center network expansion, which is key to securing raw materials and increasing production.
Monthly dynamics of market capitalization of the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies for the treatment of immunodeficiency patients. They operate in a highly specialized and vital market. The chart below illustrates the overall dynamics of the biotech sector, where innovations in the treatment of rare diseases are attracting investor attention.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of companies producing blood plasma-derived drugs can be stable due to consistent demand. The chart below shows general market fluctuations. Does ADMA Biologics demonstrate this stability, or does its status as a biotech make it more volatile?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ADMA Biologics
ADMA Biologics, a biopharmaceutical company specializing in plasma-derived products, is the focus of healthcare news. Its weekly stock price reflects FDA decisions, product efficacy data, and plasma donation-related news, creating high volatility.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Biopharmaceutical companies specializing in plasma-derived products, like ADMA Biologics, operate in a niche but important market. The chart below illustrates the overall sentiment in this segment. It allows one to assess how successfully ADMA is growing production and sales compared to other players in this specific industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ADMA Biologics produces and sells plasma-based medications. This is a specialized and stable segment of the pharmaceutical industry. The chart helps assess how insulated the company's shares are from overall market volatility thanks to its unique and vital niche.
Market capitalization of the company, segment and market as a whole
ADMA - Market capitalization of the company ADMA Biologics
ADMA Biologics' market capitalization is the market's valuation of its niche business producing plasma-based therapies. The chart reflects how investors value its specialized immunoglobulins for treating rare diseases. An increase in this metric indicates increased plasma collection and sales of its life-saving medications.
ADMA - Share of the company's market capitalization ADMA Biologics within the market segment - Pharma immune
ADMA Biologics occupies a niche but critically important share of the plasma immunoglobulin market. The company's market capitalization reflects its ability to produce and market specialized medications for patients with immunodeficiency.
Market capitalization of the market segment - Pharma immune
This graph shows the total value of the entire biotech sector focused on plasma-based therapies. For ADMA Biologics, which operates in this narrow but vital niche, this line represents the size of its market. The rising graph reflects the growing demand for immunoglobulins to treat people with weakened immune systems.
Market capitalization of all companies included in a broad market index - GURU.Markets
ADMA Biologics produces plasma-based drugs for the treatment of immune diseases. Its market capitalization is the market valuation of life-saving, niche drugs. Globally, this represents the market share of businesses saving the lives of people with rare diseases.
Book value capitalization of the company, segment and market as a whole
ADMA - Book value capitalization of the company ADMA Biologics
ADMA Biologics produces blood plasma products, and its book value is its production and research base. This includes plasma collection centers, fractionation plants, and R&D laboratories. This is the material foundation for saving lives. How has this specialized asset grown? The chart below shows the dynamics of this process.
ADMA - Share of the company's book capitalization ADMA Biologics within the market segment - Pharma immune
ADMA Biologics is not just an R&D company, but a vertically integrated biopharmaceutical company. Its balance sheet reflects the value of its plasma collection centers, as well as its own fractionation and purification plant for immunoglobulin production. The chart shows its share of the physical infrastructure for plasma-derived drug production.
Market segment balance sheet capitalization - Pharma immune
ADMA Biologics is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are capital-intensive. ADMA is a vertically integrated player. Unlike many, it not only develops drugs but also owns a network of plasma collection centers, which is its unique asset.
Book value of all companies included in the broad market index - GURU.Markets
ADMA Biologics produces life-saving medications from blood plasma, and its assets comprise the production chain itself. Its book value includes plasma collection centers, fractionation plants, and quality control laboratories. The chart shows the physical weight of this biopharmaceutical company in a critical healthcare niche.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ADMA Biologics
ADMA Biologics owns plasma collection centers and manufacturing facilities. But the market is evaluating not only these but also the potential of its patented drugs. The chart shows how expectations for sales growth for these unique products create a premium for its purely manufacturing assets.
Market to book capitalization ratio in a market segment - Pharma immune
ADMA Biologics is a company that produces and sells plasma-based therapies. Its value lies in its specialized products, manufacturing processes, and patents. This chart shows how much investors believe in its niche business model beyond the value of its laboratories and equipment.
Market to book capitalization ratio for the market as a whole
ADMA Biologics is a company that collects blood plasma and produces specialized immunoglobulins for the treatment of immunodeficient patients. The company's business is at the intersection of biotechnology and healthcare. This chart shows overall valuations, but how do investors view a company whose product is vital for a small group of patients?
Debts of the company, segment and market as a whole
ADMA - Company debts ADMA Biologics
ADMA Biologics operates in the capital-intensive field of plasma-derived product manufacturing. Scaling this business requires significant investment. This chart shows how the company is using debt capital to expand its network of plasma collection centers and modernize its production facilities to meet growing demand.
Market segment debts - Pharma immune
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies. Plasma collection and production of these medications is a complex and capital-intensive process. This chart shows how the company finances its operations and donor center network expansion compared to other biotech players.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ADMA Biologics
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies. This chart shows how the company finances its production and commercialization. For a company growing sales, debt management is essential for investments in plasma collection, manufacturing capacity, and marketing to achieve profitability.
Market segment debt to market segment book capitalization - Pharma immune
The production of plasma-based biologics, ADMA Biologics' specialty, is a complex and capital-intensive process. This chart shows the overall debt burden in the biotech sector. It allows one to assess how ADMA's financial model, with its own plasma collection network, differs from other pharmaceutical companies and how it finances its production.
Debt to book value of all companies in the market
This chart shows the average debt burden across the entire economy. ADMA Biologics operates in the capital-intensive biopharmaceutical sector, which requires investment in production. A comparison with the broader market, which is rich in "lightweight" businesses, shows how the financial policies of a company managing a complex plasma supply chain differ from the stock market average.
P/E of the company, segment and market as a whole
P/E - ADMA Biologics
This chart for ADMA Biologics, a company that produces plasma-based medications, shows how investors view its growth. The multiple reflects expectations for increased plasma collection volumes and sales of specialized immunoglobulins. This is an assessment of the company's ability to scale up production and carve out a niche in the biologics market.
P/E of the market segment - Pharma immune
The production of plasma-derived medications, as performed by ADMA Biologics, is a niche pharmaceutical business. This chart shows the average valuation for biopharmaceutical companies. It helps understand how investors view ADMA's vertically integrated model and its growth potential in the immunoglobulin market.
P/E of the market as a whole
ADMA Biologics is a biopharmaceutical company that produces and markets specialized plasma-based therapies for the treatment and prevention of infectious diseases in immunocompromised patients. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether ADMA's valuation reflects confidence in its niche products or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ADMA Biologics
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based medications for the treatment of immunodeficiency conditions. This chart demonstrates market expectations for growth in demand for its specialized products. It reflects analysts' forecasts for sales volumes and the company's ability to expand its market share in immunoglobulins.
%20P%2FE%20ADMA%20Biologics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ADMA-Biologics&v=1772626568758 "Chart of the company's future (projected) P/E ADMA Biologics")
Future (projected) P/E of the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-derived therapies for the treatment of immunodeficiency conditions. This chart shows its expected future profitability compared to other pharmaceutical companies. Does this estimate take into account its specialized manufacturing process and market niche?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772626568777 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
ADMA Biologics collects blood plasma and produces specialized immunoglobulins for the treatment of immunodeficient patients. Demand for its products is vital and independent of economic conditions. Against the backdrop of general market expectations, ADMA's business is driven by the specifics of the healthcare system and patient needs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772626568781 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ADMA Biologics
ADMA Biologics produces and markets plasma-based products, specifically immunoglobulins. The company's profits depend on plasma collection volumes, the efficiency of its fractionation, and market prices for the final products. This chart shows how the company is ramping up production and sales, striving to achieve stable profitability in its niche.
Profit of companies in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies for the treatment of immunodeficiency conditions. Its business has a high barrier to entry. This chart reflects the general dynamics of the niche biopharmaceutical sector, where specialized products and stable demand ensure sustainable profitability.
Overall market profit
ADMA Biologics produces and sells plasma-based products. Demand for its products is relatively stable, driven by medical needs. However, the overall economic situation, as reflected in the graph, impacts the healthcare system, government budgets, and the solvency of insurance companies, which indirectly affects ADMA.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ADMA Biologics
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies for the treatment of immunodeficiency conditions. These are vital products for a select group of patients. This chart summarizes analyst opinions on the future growth of the immunoglobulin market and ADMA's ability to scale up production and sales.
%20profit%20of%20the%20company%20ADMA%20Biologics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ADMA-Biologics&v=1772626568873 "Graph of future (projected) profit of the company ADMA Biologics")
Future (predicted) profit of companies in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies for the treatment of immunodeficiency conditions. The company operates its own network of plasma collection centers. This chart shows profitability projections for the pharmaceutical sector, providing context for assessing ADMA's niche business model in the plasma-based industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772626568889 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
ADMA Biologics specializes in the production and sale of plasma-based medications. Demand for its products is driven by the medical needs of immunocompromised patients and is independent of economic conditions. This makes ADMA's business recession-resistant and unrelated to general market expectations, as reflected in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772626568899 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ADMA Biologics
ADMA Biologics specializes in plasma-derived products. This chart shows how the market values the sales of its specialized biologics. For such a company, the ratio reflects not only current sales but also the growth potential of its unique products and production capacity.
P/S market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets plasma-based therapies for the treatment of immunodeficiency diseases. This chart shows the average revenue estimate in the biotech sector. It helps understand how the market views ADMA's unique, vertically integrated business and the growth potential of its specialized products.
P/S of the market as a whole
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies for the treatment of immunodeficiency diseases. Their business is critical for patients. This chart provides insight into market revenue estimates, which can be used to assess how investors value specialty and niche pharmaceutical companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ADMA Biologics
ADMA Biologics is a biopharmaceutical company that collects blood plasma and produces specialized medications for the treatment of immunodeficiency conditions. This chart reflects market expectations for future sales of its products. The estimate depends on plasma collection volumes, production efficiency, and demand for its vital immunoglobulins.
%20P%2FS%20ADMA%20Biologics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ADMA-Biologics&v=1772626568935 "The graph of the company's future (projected) P/S ADMA Biologics")
Future (projected) P/S of the market segment - Pharma immune
ADMA Biologics develops and markets specialized plasma-derived biologics for the treatment of immunocompromised patients. The company occupies an important niche in the biopharmaceutical industry. This chart compares how the market values the future sales of its specialized products compared to the broader biopharmaceutical sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772626568938 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
ADMA Biologics is a biopharmaceutical company specializing in plasma-based therapies for the treatment of immunodeficiency conditions. This chart, reflecting overall economic confidence, impacts healthcare funding. Stable economic growth ensures reliable funding for healthcare systems, allowing patients to access specialized and expensive medications like ADMA's.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772626568958 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ADMA Biologics
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based medications for the treatment of immunodeficiency conditions. This chart reflects revenue from sales of these vital medications, as well as from the operation of a network of plasma collection centers. The growth here reflects increased demand for immunoglobulins and the successful expansion of production capacity.
Sales of companies in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialized plasma-based therapies, such as immunoglobulins. Its business can be broken down by specific products. This chart shows revenue from one of its key products, allowing one to assess its commercial success and market demand.
Overall market sales
ADMA Biologics is a biopharmaceutical company producing plasma-based therapies for the treatment of immunodeficiency disorders. Demand for its products is vital and independent of economic conditions. The company operates in a niche yet critically important area of healthcare, demonstrating how specialized medicine contributes to public well-being.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ADMA Biologics
ADMA Biologics is a biopharmaceutical company specializing in the production and sale of plasma-based therapies for the treatment of immunodeficiency conditions. Its revenue forecast is based on plasma collection volumes and sales of its specialized immunoglobulins. It reflects the expected growth of the plasma product market and demand for its therapies.
%20sales%20of%20the%20company%20ADMA%20Biologics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ADMA-Biologics&v=1772626569009 "Schedule of future (projected) sales of the company ADMA Biologics")
Future (projected) sales of companies in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company specializing in the production and sale of plasma-based therapies. This chart shows revenue expectations for the immunotherapy sector. It reflects analysts' views on demand for immunoglobulins and other plasma-based products, allowing them to assess the overall state of this specialized market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772626569030 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
ADMA Biologics produces plasma-based medications. Demand for its products is stable, but growth depends on the expansion of diagnostics and treatment availability. This chart of overall sales forecasts reflects the state of the economy, which impacts healthcare budgets and the system's ability to provide patients with expensive medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772626569062 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ADMA Biologics
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies for the treatment of immunodeficiency diseases. This chart shows how the company converts sales revenue from its specialized products into profit while managing the complex process of plasma collection, manufacturing, and regulatory requirements.
Market segment marginality - Pharma immune
ADMA Biologics is a biopharmaceutical company that collects blood plasma and produces specialized medications for the treatment of immunodeficiency conditions. Vertical integration (from plasma collection to drug sales) gives the company control over quality and costs. This chart demonstrates how effective this business model is in their specialized sector.
Market marginality as a whole
ADMA Biologics is a biopharmaceutical company producing plasma-based medications for the treatment of immunodeficiency diseases. The company's profitability depends on plasma collection volumes and demand for its specialized products. This chart shows overall profitability, but for ADMA, its ability to secure critical drug supplies determines its market position.
Employees in the company, segment and market as a whole
Number of employees in the company ADMA Biologics
ADMA Biologics produces and markets plasma-based products. This chart shows the growth of its team as it expands its production capacity and plasma collection center network. This expansion is key to meeting demand for its specialized immunoglobulins.
Share of the company's employees ADMA Biologics within the market segment - Pharma immune
ADMA Biologics specializes in the production and sale of plasma-based products. Plasma collection and immunoglobulin production are complex and labor-intensive processes. This reflects its niche yet important role as an employer in the biopharmaceutical industry, where its employees help save lives.
Number of employees in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company specializing in the production and development of plasma-based therapies. This chart reflects employment in the immunology sector. The growing number of specialists in this field reflects the growing importance of immunotherapy and the high demand for life-saving treatments, providing a foundation for ADMA's business growth.
Number of employees in the market as a whole
ADMA Biologics produces plasma-based medications. Demand for their products is driven by medical needs, not the economy. However, a strong labor market, as illustrated by this chart, means more people have health insurance, ensuring patient access to expensive medications and stable payments for ADMA.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ADMA Biologics (ADMA)
ADMA Biologics produces plasma-based drugs. This complex biotech and manufacturing process is a key component of its overall development. This graph, showing the company's capitalization per employee, reflects the balance between the value of its specialized manufacturing facilities, intellectual property, and the efficiency of its scientific and technical staff.
%20of%20the%20company%20ADMA%20Biologics%20(ADMA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ADMA-Biologics-ADMA&v=1772626569401 "Chart of market capitalization per employee (in thousands of dollars) of the company ADMA Biologics (ADMA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
ADMA Biologics (ADMA) is a "plasma" company. It collects blood plasma (a labor-intensive process) and produces specialized drugs from it (a capital-intensive process). It's a hybrid "vertical" pharma business. This chart shows the market value per employee in this complex, "heavy" model.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772626569408 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based medications. It's a complex manufacturing and regulatory environment. The chart reflects the market's assessment of the company's ability to operate in this highly specialized and capital-intensive healthcare niche.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772626569415 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ADMA Biologics (ADMA)
ADMA Biologics is a biopharmaceutical company that produces and markets specialized plasma-based therapies (immunoglobulins). They have both their own products and a network of plasma collection centers. This chart demonstrates how efficiently they manage this vertically integrated model—from plasma collection to manufacturing and sales of finished drugs—transforming the labor of their specialists into pure profit.
%20Chart%20ADMA%20Biologics%20(ADMA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ADMA-Biologics-ADMA&v=1772626569437 "Company Profit Per Employee (in thousands of dollars) Chart ADMA Biologics (ADMA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
ADMA Biologics is a "plasma" company. They collect blood plasma and produce "immunoglobulin" from it. This graph shows the benchmark for "Pharma-immune" (Plasma). In this B2B sector, the benchmark is moderate. This is a "manufacturing" biotech, where profit per employee (at the collection center or plant) depends on plasma prices and fractionation efficiency.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772626569439 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
ADMA Biologics (ADMA) is a biopharmaceutical company specializing in plasma-derived drugs. They collect plasma and produce immunoglobulins for the treatment of immunodeficient patients. This graph, showing average profit per employee, is important for biotech. It allows one to assess how profitable a sector that relies on raw material collection and complex manufacturing is relative to its workforce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772626569467 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ADMA Biologics (ADMA)
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived products. This chart demonstrates the effectiveness of its vertically integrated model. The growth in revenue per employee reflects the company's ability to control the entire value chain, from plasma collection to the production and sale of life-saving immunoglobulins.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ADMA-Biologics-ADMA&v=1772626569475 "Sales chart per company employee ADMA Biologics (ADMA)")
Sales per employee in the market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company specializing in plasma-based products, specifically immunoglobulins for the treatment of immunodeficiency. This chart compares ADMA's revenue per employee to the industry average. This reflects the efficiency of their plasma collection and manufacturing process compared to other players in this specific market.
Sales per employee for the market as a whole
ADMA Biologics is a biopharmaceutical company that produces and markets plasma-based therapies (immunoglobulins) for the treatment of immunodeficiency conditions. This is a complex biological manufacturing process. This chart shows how efficiently their commercial team and manufacturing facilities (including their own plasma collection centers) generate revenue.
Short shares by company, segment and market as a whole
Shares shorted by company ADMA Biologics (ADMA)
ADMA Biologics is a biopharmaceutical company that collects blood plasma and produces specialized drugs (immunoglobulins) from it. This is a niche market. Investors are weighing the potential for demand growth against the challenges of plasma collection and competition. This chart shows the percentage of those who doubt ADMA's ability to grow profitably.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ADMA-Biologics-ADMA&v=1772626569702 "Short Shares Chart for the Company ADMA Biologics (ADMA)")
Shares shorted by market segment - Pharma immune
ADMA Biologics is a biopharmaceutical company that collects and purifies blood plasma to create specialized immunoglobulins for the treatment of people with weakened immune systems. This chart shows the odds against the plasma-based drug sector. It reflects concerns about competition, pricing pressure, and plasma collection issues.
Shares shorted by the overall market
ADMA Biologics (ADMA) is a biopharmaceutical company (plasma products). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with stable drug revenues, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ADMA Biologics (ADMA)
ADMA Biologics, which specializes in plasma-derived therapies, operates in the niche but important healthcare sector. This chart helps gauge sentiment around ADMA stock. A reading above 70 may reflect optimism following strong sales or new product approval, but it can also signal overbought conditions. A reading below 30 may indicate panic due to concerns about funding or competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ADMA-Biologics-ADMA&v=1772626569792 "RSI 14 indicator chart for the company's stock ADMA Biologics (ADMA)")
RSI 14 Market Segment - Pharma immune
ADMA Biologics specializes in plasma immunoglobulins, vital for patients with weakened immune systems. The "Pharma-immune" sector is highly sensitive to news. RSI_14_Seg reveals whether the entire biotech segment is overheated. The chart helps us understand whether ADMA's growth is a response to its production successes or simply general hype in the sector.
RSI 14 for the overall market
ADMA Biologics (ADMA) produces plasma-based medications. This chart is an indicator of capital availability for biotech. Although demand for its products is stable, the company needs funding for growth. During periods of euphoria, ADMA can easily raise capital. In times of panic, investors avoid the sector, making expansion difficult.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADMA (ADMA Biologics)
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived products, specifically immunoglobulins for the treatment of immunocompromised patients. This chart shows the average analyst forecast. Their target prices are based on growing sales of approved drugs and the expansion of their network of plasma collection centers.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADMA-ADMA-Biologics&v=1772626569838 "A chart showing analyst consensus forecasts for the expected stock price. ADMA (ADMA Biologics)")
The difference between the consensus estimate and the actual stock price ADMA (ADMA Biologics)
ADMA Biologics (ADMA) is a biopharmaceutical company that collects blood plasma and produces specialized drugs (immunoglobulins) for the treatment of immunodeficiency. This chart shows their niche valuation. It measures the gap between the price and the consensus target, reflecting the growth potential analysts see in their plasma-based drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADMA-ADMA-Biologics&v=1772626569866 "A chart showing the difference between the consensus forecast and the actual stock price. ADMA (ADMA Biologics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
ADMA Biologics is a specialized biopharmaceutical company. It collects blood plasma and produces immunoglobulins—medications for people with weakened immune systems. This chart shows analysts' overall expectations for the immune pharma sector. It reflects whether experts believe demand for these vital medications will grow.
Analysts' consensus forecast for the overall market share price
ADMA Biologics is a company that specializes in collecting blood plasma and producing immunoglobulins—medications for patients with weakened immune systems. This chart shows the overall market sentiment. For ADMA, which operates in a highly specialized but protective healthcare sector, general optimism is important for funding, but demand for its products is stable.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ADMA Biologics
ADMA Biologics is a specialized biopharmaceutical company. They collect blood plasma and use it to produce immunoglobulins—medicines essential for people with weakened immune systems. This chart evaluates their niche model. It reflects their ability to scale up plasma collection (opening new centers) and increase sales of their patented immunotherapy drugs.
AKIMA Market Segment Index - Pharma immune
ADMA Biologics is a niche biopharma company; the company collects blood plasma and produces specialized medications (immunoglobulins) for patients with immune disorders. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does ADMA's vertically integrated (plasma) model differentiate it from the average pharma company?
The AKIM Index for the overall market
ADMA is a plasma company. It collects blood plasma and produces medications (immunoglobulins) for patients with immune deficiencies. This chart, which reflects the market average, is a backdrop. It helps assess how this defensive (non-cyclical) biotech business compares to the overall macroeconomic fluctuations reflected by this indicator.
